Navigation Links
PSA Screening Cuts Deaths by 20%, Says World's Largest Prostate Cancer Study
Date:3/18/2009

STOCKHOLM, Sweden, March 18 /PRNewswire/ --

- Attn: Healthcare Editors

Screening for prostate cancer can reduce deaths by 20%, according to the results of the European Randomized Study of Screening for Prostate Cancer (ERSPC) published online 1700 hours CET 18 March (NEJM, Online First*). ERSPC is the world's largest prostate cancer screening study and provides robust, independently- audited evidence, for the first time, of the effect of screening on prostate cancer mortality.

The study commenced in the early 1990s involving eight countries - Belgium, Finland, France, Italy, Netherlands, Spain, Sweden and Switzerland - with an overall follow-up of up to 12 years. Participants totalled 182,000 but then narrowed down to 162,000 men in seven countries, aged 55-69; only those who had not been screened could take part. The findings are being unveiled at the annual European Urology Congress in Stockholm, Sweden (17 - 21 March 2009).

By initially screening men 55 to 69 years with the PSA marker and offering regular follow up, this led to an increase in early detection. Deaths due to metastasized disease were then reduced. Exact data showed that on average for every 1,408 men screened, 48 had cancer diagnosed and received treatment, resulting in saving one life. Screening took place on average every four years with a mean follow-up over nine years. The cut-off value was a PSA level of 3.0 ng/ml or more. Men with this reading were then offered a biopsy.

Prof Fritz Schroder, international coordinator of the ERSPC study explained: "The study shows that PSA screening delivers a 20% reduction in mortality from prostate cancer. This provides decision makers on screening policies with important new data on the effectiveness of PSA testing in preventing deaths.

"However, The ERSPC is also near to completing additional studies on quality of life and cost-effectiveness and these must be assessed before making a decision about the appropriateness of a national prostate screening policy."

Worldwide, prostate cancer is the second leading cause of cancer death. Separate ERSPC findings already confirm that approximately 30% of detected cancers actually have non-aggressive features and are 'indolent' or slow growing. This overdiagnosis is an unavoidable effect from all cancer screening procedures. With prostate cancer, a new, more conservative form of monitoring, 'Active Surveillance', might be an important method to help avoid early invasive treatment (www.erspc.org).

*http://content.nejm.org/cgi/content/full/NEJMoa0810084


'/>"/>
SOURCE ERSPC (European Randomized Study of Screening for Prostate Cancer)
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Suggests New Antigen-Antibody Combo Test Useful for High Volume Public Health Screening
2. Lenetix Launches Screening Study of New Down Syndrome Test
3. Breakthrough in Prenatal Screening for Down Syndrome
4. ASGE Encourages Patients to Speak to Their Doctor About Colorectal Cancer Screening Options
5. Screening for Ischemia in Asymptomatic Patients With Type 2 Diabetes: Five- Year Outcomes in the DIAD Study
6. FDA Reviewing Biomoda Submission for Cancer Screening Study
7. Task Force Recommends Screening for Hearing Loss in All Newborns
8. Karmanos Doctors Urge Increased Screening for Previously Treated Lung Cancer Patients, Especially Young Women
9. Adding Breast Ultrasound Screening to Mammography Reveals Cancers not Seen on Mammography Alone in Women at Increased Risk for Breast Cancer
10. Blood Spot Technology at ZRT Highlighted in March Issue of Journal of Diabetes Science & Technology - A Convenient Alternative to Serum Testing for Health Screening
11. Lung Cancer Alliance Commends NCCN on Screening Guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... 2016 Global Paclitaxel Market 2016 ... 12 companies and the Paclitaxel analysis in this study ... industry and its players. This is the ... details the current state of the industry while providing ... applications and industry chain structure. The Paclitaxel market analysis ...
(Date:5/23/2016)... 2016 According to market ... Growth and Demand Forecast to 2022 - Industry ... Application (Drug Discovery and Development, Proteomics, Clinical Testing, ... Science and Biotechnology, Academic and Research Institute, Hospitals ... global mass spectrometry market was valued ...
(Date:5/23/2016)... 2016 Non-invasive diagnostic test realizes ... diseases; ,Technology to be presented at Yissum’s booth, at ... Development Company of the Hebrew University of Jerusalem ... with Aurum Ventures MKI, the technology investment arm of ... diagnostic approach for early detection of multiple diseases by ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... ... it will join America's leading engineers at the American Society of Safety Engineers ... World Congress Center. , Engineers, speakers and exhibitors from more than 40 ...
(Date:5/24/2016)... , ... May 24, 2016 , ... ... its inaugural health care blockchain event, Distributed: Health, to be held in Nashville, ... downtown Symphony Center. , A 24-hour Hackathon preceding the event will host teams ...
(Date:5/24/2016)... ... May 24, 2016 , ... i2i, a national leader in ... its “Transforming Outcomes” User Conference in Las Vegas on May 19-20, 2016. ... set the market standard for meaningful population health management. The company recently ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... Center at Sentara Northern Virginia Medical Center located in Woodbridge, VA. The ... surgical services into a single site. , The new 2 story building houses ...
(Date:5/24/2016)... Irvine, CA — , ... ... the appointment of three new members of its Advisory Board. ... Chico and Sarah Kusch. “All three of them embody the mission ... team. We are very fortunate to have them as we continue ...
Breaking Medicine News(10 mins):